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Massachusetts, USA. 3Department of Pathology, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA. 4Department of Pathology, Anatomy, and Cell Biology,
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Compromised apoptotic signaling is a prerequisite for tumorigenesis. The design of effective therapies for cancer treatment
depends on a comprehensive understanding of the mechanisms that govern cell survival. The antiapoptotic proteins of
the BCL-2 family are key regulators of cell survival and are frequently overexpressed in malignancies, leading to increased
cancer cell survival. Unlike BCL-2 and BCL-XL, the closest antiapoptotic relative BCL-W is required for spermatogenesis, but
was considered dispensable for all other cell types. Here, however, we have exposed a critical role for BCL-W in B cell survival
and lymphomagenesis. Loss of Bcl-w conferred sensitivity to growth factor deprivation–induced B cell apoptosis. Moreover,
Bcl-w loss profoundly delayed MYC-mediated B cell lymphoma development due to increased MYC-induced B cell apoptosis.
We also determined that MYC regulates BCL-W expression through its transcriptional regulation of specific miR. BCL-W
expression was highly selected for in patient samples of Burkitt lymphoma (BL), with 88.5% expressing BCL-W. BCL-W
knockdown in BL cell lines induced apoptosis, and its overexpression conferred resistance to BCL-2 family–targeting BH3
mimetics. Additionally, BCL-W was overexpressed in diffuse large B cell lymphoma and correlated with decreased patient
survival. Collectively, our results reveal that BCL-W profoundly contributes to B cell lymphoma, and its expression could serve
as a biomarker for diagnosis and aid in the development of better targeted therapies.

Introduction

mary mouse hematopoietic cells and to observations that Bcl-w–
deficient mice have no overt hematopoietic defects (6, 7). While
BCL-W is recognized for its critical function in spermatogenesis
(8, 9), there is emerging evidence to suggest that BCL-W may also
have a role in tumorigenesis. Specifically, BCL-W overexpression
cooperated with MYC to accelerate the development of myeloid
leukemia (10). In addition, BCL-W overexpression was observed
in patient samples of gastric and colorectal adenocarcinoma (11,
12) and in several human solid tumor cell lines (13). These data
indicate that BCL-W may contribute to human cancers, but which
malignancies and whether BCL-W contributes to tumorigenesis
and cancer cell survival remain unclear.
Here, we report a previously unknown role for BCL-W in
MYC-induced apoptosis and lymphomagenesis that we believe will
have significant clinical implications. By evaluating BCL-W expression in human B cell lymphomas in combination with mouse modeling to directly assess the contribution of BCL-W in MYC-driven
lymphomagenesis, we determined that BCL-W has a significant
role in B cell lymphoma development and survival. Furthermore,
we identified a mechanism by which MYC regulates BCL-W expression. Our data illuminate an unappreciated link between MYC and
BCL-W that we believe significantly extends the knowledge of MYC
and the role of BCL-W in tumorigenesis, both of which should aid
in improving lymphoma prognostics, diagnostics, and therapeutics.
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Results

Apoptosis is a well-orchestrated process regulated by multiple
genes, particularly those belonging to the BCL-2 family. The inherent ability of cells to undergo apoptosis in response to cellular
stresses, including activation of oncogenes such as MYC, functions
as a safeguard against tumorigenesis (1). Consequently, alterations
resulting in aberrant expression of antiapoptotic BCL-2 family
members and/or loss of expression of proapoptotic BCL-2 family
members are well documented in most human cancers (2). The
BCL-2 family has an established role in determining whether cells
should live or die. However, knowledge about whether specific
BCL-2 family members (other than BCL-2 itself) are dysregulated
in or contribute to human malignancies and how this information
can be exploited therapeutically remains incomplete.
Dysregulated MYC expression occurs in at least 70% of human
malignancies and is a known driver of Burkitt lymphoma (BL) (3).
The Eμ-MYC–Tg mouse model of MYC-induced B cell lymphomagenesis (4) has been instrumental in delineating the roles of BCL-2
family proteins in lymphoma, which has translated to many other
human cancers (5). However, relative to other BCL-2 family members, little information is known about the role of the antiapoptotic
protein BCL-W in cell survival and lymphomagenesis. This is likely due to early reports showing low expression of BCL-W in pri-

Cytokine deprivation–induced apoptosis is accelerated by loss of BCL-W.
BCL-W levels were reported to be low in lymphocytes and dispensjci.org   Volume 127   Number 2   February 2017
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Figure 1. Cytokine deprivation–induced pre–B cell death is accelerated by loss of Bcl-w. BM from Bcl-w+/+, Bcl-w+/–, and Bcl-w–/– littermates was placed
into IL-7–containing media on day 0. Western blotting was performed on pre–B cells that grew out of the cultures (A). Cells were counted at intervals,
population doublings were calculated (B), and viability (C) was determined by trypan blue dye exclusion. (D and E) Equal numbers of pre–B cells of each
genotype were plated with (D) or without (E) IL-7. MTS assays were performed in quadruplicate at intervals (left, D and E). Total viable cell numbers (middle, D and E) and viability (right, D and E) were measured with trypan blue in triplicate at the indicated intervals. Data shown are representative results of 2
to 4 independent experiments from cells isolated from 2 separate litters generated by different parents. Error bars indicate the SD. For E, *P < 0.0001,
#
P < 0.0004, and §P < 0.0009, by 1-way ANOVA.

able for lymphocyte survival due to a lack of defects in Bcl-w–null
mice (6–8). However, we directly tested whether BCL-W contributed to the survival of B cells by generating cultures of primary pre–B
cells isolated from BM of littermate-matched Bcl-w+/+, Bcl-w+/–, and
Bcl-w–/– mice. BCL-W protein was readily detectable in WT pre–B
cells (Figure 1A). BCL-W levels decreased by approximately half
with loss of 1 allele of Bcl-w and were absent in the Bcl-w–null pre–B
cells. The levels of other antiapoptotic BCL-2 family members were
unaltered in the Bcl-w–deficient cells (Figure 1A). The growth rates
and viability of the 3 genotypes of pre–B cells cultured under normal
conditions were indistinguishable from each other (Figure 1, B–D).
However, loss of Bcl-w affected cell survival following withdrawal
of IL-7, an essential cytokine. Specifically, Bcl-w–null pre–B cells had
significantly reduced cell expansion following IL-7 withdrawal, due
to decreased cell numbers and viability (Figure 1E). Bcl-w heterozygous pre–B cells showed an intermediate reduction in growth and
survival compared with WT and Bcl-w–/– pre–B cells after IL-7 withdrawal (Figure 1E). These results indicate that a loss of Bcl-w potentiates the negative consequences of cytokine deprivation in B cells
and that BCL-W contributes to B cell survival.
MYC-induced apoptosis is augmented by loss of BCL-W. To determine whether loss of Bcl-w would confer sensitivity to other apop636
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totic stimuli such as hyperproliferative signals from oncogenes
like MYC, we induced the expression of a 4-hydroxytamoxifen–
inducible (4-OHT–inducible) form of MYC (MYCER) (14) in primary pre–B cell cultures from littermates (Figure 2A). Following
activation of MYCER with 4-OHT, we observed a robust apoptotic
response in pre–B cells lacking both alleles of Bcl-w. There was a
decrease in cell growth (Figure 2A), total cell numbers (Figure 2B),
and viability (Figure 2C) in the MYCER-activated Bcl-w –/– pre–B
cells compared with WT pre–B cells. Moreover, the Bcl-w–null
pre–B cells showed an increase in annexin V–positive cells (Figure
2D) and a more rapid appearance of cleaved caspase 3 (Figure 2E)
following MYCER activation. We observed a modest, but significant, decrease in cell growth and survival in Bcl-w+/– pre–B cells
compared with WT pre–B cells following MYCER activation (Figure 2, A–E). These data demonstrate that BCL-W is critical for B
cell survival in the presence of MYC dysregulation.
To further test the role of BCL-W in MYC-induced apoptosis in B cells, we derived pre–B cells from the BM of littermate-matched Bcl-w+/+, Bcl-w+/–, and Bcl-w –/– Eμ-MYC mice, which
overexpress MYC specifically in B cells (4), prior to any sign of
lymphoma development. Within 12 days after explantation into
culture, pre–B cells (B220+CD19+CD43–IgM–) dominated the cul-
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Figure 2. MYC-induced apoptosis is augmented by loss of Bcl-w. (A–E) BM-derived pre–B cells from Bcl-w+/+, Bcl-w+/–, and Bcl-w–/– littermates were infected
with the 4-OHT–inducible MYCER. Western blot analysis was performed (A). Equal numbers of cells of each genotype were placed into culture. Following the
addition of 4-OHT to activate MYCER, MTS assays (A) were performed in quadruplicate, total viable cell numbers (B) and viability (C) were determined using
trypan blue dye (in triplicate), and annexin V positivity (in triplicate) (D) and caspase 3 cleavage (CC3) (E) were evaluated. (F–J) BM from Bcl-w+/+ Eμ-MYC,
Bcl-w+/– Eμ-MYC, and Bcl-w–/– Eμ-MYC–Tg littermates prior to any detectable lymphoma was placed into culture on day 0, and cells were counted at intervals. Western blot analysis was performed on the pre–B cells that grew out of the cultures (F). Population doublings were calculated (F) and viability was
determined by trypan blue dye exclusion (G). (H) Equal numbers of pre–B cells of each genotype were plated and MTS assays (quadruplicate) performed. (I
and J) At the indicated intervals, cells were collected and annexin V positivity (I) and cleaved caspase 3 (J) assessed. Data shown are representative of 3 to 4
independent experiments using cells isolated from 3 separate litters generated by different parents. Error bars indicate the SD. *P < 0.0001 for A, *P < 0.029
for B, *P < 0.003 for C, *P < 0.028 for D (comparing 4-OHT–treated samples), *P < 0.0001 for H, and *P < 0.0002 for I, by 1-way ANOVA.

tures for all 3 genotypes (Supplemental Figure 1; supplemental
material available online with this article; https://doi.org/10.1172/
JCI89486DS1), indicating that loss of Bcl-w did not impair the
ability of BM cells to differentiate into pre–B cells when MYC was
overexpressed. However, when we evaluated pre–B cell growth
by assessing the net population doublings beginning the day BM
was isolated, we determined that Bcl-w –/– Eμ-MYC pre–B cells were
unable to expand in culture (Figure 2F) due to decreased viability (Figure 2G). Even loss of 1 Bcl-w allele was sufficient to impair
Eμ-MYC pre–B cell growth and survival (Figure 2, F and G). We

obtained similar results when equal numbers of Eμ-MYC pre–B
cells from each genotype were cultured and evaluated each day
for 6 days (Figure 2H).
At intervals throughout the duration of these experiments, we
assessed Eμ-MYC pre–B cells of each genotype for characteristics
of apoptosis. We determined that loss of Bcl-w led to a significant
increase in apoptosis over time compared with the WT counterpart, as evidenced by an increased number of annexin V–positive
cells (Figure 2I) and the appearance of cleaved caspase 3 (Figure
2J). In addition, Bcl-w+/–Eμ-MYC pre–B cells also showed an elejci.org   Volume 127   Number 2   February 2017
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Figure 3. Loss of Bcl-w profoundly delays MYC-driven lymphomagenesis. (A) Kaplan-Meier survival curves of Bcl-w+/+ Eμ-MYC, Bcl-w+/– Eμ-MYC, and
Bcl-w–/– Eμ-MYC–Tg mice. P < 0.0001, comparing all 3 genotypes with each other; P < 0.0001, comparing Bcl-w–/– Eμ-MYC with Bcl-w+/+ Eμ-MYC; P = 0.0338,
comparing Bcl-w+/– Eμ-MYC with Bcl-w+/+Eμ-MYC, by log-rank test. (B and C) Lymphomas of the indicated genotypes were subjected to (B) immunophenotyping to determine the type of lymphoma that emerged and (C) Western blotting to determine p53 and ARF status. Controls included a lymphomacontaining mutant p53 and p53–/– Mdm2–/– MEFs. Representative Western blots are shown; additional blots are shown in Supplemental Figure 4A. Summarized results of Western and Southern blotting are provided in Table 1.

vated apoptotic index, as these cultures had increased annexin V
staining (Figure 2I) and caspase 3 cleavage (Figure 2J) compared
with Bcl-w+/+ Eμ-MYC pre–B cell cultures. These results further
demonstrate that BCL-W has an essential role in B cell survival
and inhibition of MYC-induced apoptosis.
To assess whether the effects of loss of Bcl-w following
MYC dysregulation were B cell specific, we evaluated MYCERexpressing murine embryonic fibroblasts (MEFs). First, we
assessed whether a deficiency in Bcl-w altered the response
to MYCER activation under normal growth conditions (full
serum). While WT MEFs had decreased growth and viability and
increased apoptosis following MYCER activation, the effects
were more robust in Bcl-w–null MEFs (Supplemental Figure 2,
A–F). The apoptotic response was also accelerated in Bcl-w heterozygous MEFs following MYCER activation compared with
the response observed in Bcl-w+/+ MEFs (Supplemental Figure
2, A–F). Under serum-free conditions, Bcl-w–null MEFs rapidly
underwent apoptosis following MYCER activation (Supplemental Figure 2, A–C). After only 24 hours of MYCER activation, no
viable cells remained in the Bcl-w –/– MEF cultures, whereas a third
of their WT counterparts were still viable. Together, these results
show that BCL-W is not only important for the survival of B cells,
but also contributes significantly to the survival of nonhematopoietic cells in response to dysregulated MYC.
Loss of BCL-W profoundly delays MYC-driven lymphoma development. Given that loss of Bcl-w substantially increased the susceptibility of B cells to MYC-induced apoptosis, we postulated
that a deficiency in Bcl-w would negatively affect MYC-driven B
cell lymphoma development. To test this hypothesis, we generated a cohort of littermate-matched Eμ-MYC–Tg mice with 2, 1,
638
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or no Bcl-w alleles. Bcl-w –/– Eμ-MYC mice had an extremely long
delay in lymphoma development (Figure 3A; P < 0.0001, log-rank
test). This delay in MYC-induced lymphomagenesis resulted in a
mean survival of 298.5 days for Bcl-w –/– Eμ-MYC mice, which was
3.3 times longer than the mean survival of their Bcl-w+/+ Eμ-MYC
littermates (90.0 days). Of note, all of the Bcl-w+/+ Eμ-MYC mice
developed lymphoma and were sacrificed before the first Bcl-w –/–
Eμ-MYC mouse presented with lymphoma. Loss of just 1 Bcl-w
allele also significantly delayed MYC-induced B cell lymphoma
development (Figure 3A; P = 0.0338, log-rank test; mean survival of 120.7 days). Immunophenotyping revealed no difference in
the type of B cell lymphomas that arose. Specifically, all 3 genotypes developed lymphomas characteristic of those that develop
in Eμ-MYC–Tg mice (15), with a similar distribution of pre–B cell
(B220+CD19+CD43–IgM–), B cell (B220+CD19+CD43–IgM+), and
pre–B/B cell lymphomas (Figure 3B), including lymphomas that
arose early or late. Therefore, a deficiency in Bcl-w caused a delay
in B cell lymphoma development, but did not alter the type of lymphoma that emerged.

Table 1. Reduced ARF and p53 inactivation in Bcl-w–deficient
lymphomas
Genotype

p53-mutatedA

p53-deletedB

Arf-deletedB

Bcl-w Eμ-MYC
Bcl-w+/– Eμ-MYC
Bcl-w–/– Eμ-MYC

2 of 10 (20%)
1 of 15 (7%)
1 of 20 (5%)

0 of 10 (0%)
0 of 15 (0%)
0 of 20 (0%)

2 of 10 (20%)
2 of 15 (13%)
2 of 20 (10%)

+/+

Determined by sequencing; Bdetermined by Southern blotting.

A
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Figure 4. MYC suppresses BCL-W
expression in normal cells. At intervals
following the addition of 4-OHT, WT
pre–B cells (A, left) and p53-null MEFs
(C–E) expressing either WT MYCER (A,
left, B, top, C, and D), MYCV394D-ER (C),
or MYCΔMBII-ER (D and E) were Western
blotted for the indicated proteins (A, C,
and D), and mRNA levels were measured
in triplicate by qRT-PCR (B, top, and E).
Precancerous splenocytes from Eμ-MYC–
Tg (Tg+) and non-Tg littermates (Tg–) were
subjected to Western blotting (A, right)
and qRT-PCR (in triplicate, B, bottom;
n = 4 of each). mRNA expression was
normalized to β-actin and presented as
2–ΔΔCt. Data shown are representative of 2
to 4 independent experiments. Error bars
indicate the SEM. *P < 0.0071 (B) and
*P < 0.005 (E), by t test.

To determine whether the protracted latency of lymphoma
development in mice lacking Bcl-w was due to a deficiency in B
cells, we performed immunophenotyping on 4 independent sets
of littermate-matched precancerous Eμ-MYC mice to evaluate B
cell populations. The data show no difference in the number of B
cells in the spleens of Bcl-w –/– Eμ-MYC or Bcl-w+/– Eμ-MYC mice
compared with their WT Eμ-MYC littermates (Supplemental Figure 3A). Similarly, there was no discernible difference in B cell

numbers at all stages of development
in the BM of Bcl-w–deficient Eμ-MYC
mice (Supplemental Figure 3B). Evaluation of littermate-matched, nonTg mice showed analogous results
among the 3 genotypes (Supplemental Figure 3, A and B). Therefore, a
deficiency in Bcl-w does not appear to
alter B cell development in mice with
normal or increased levels of MYC.
MYC overexpression selects
for inactivation of the ARF/p53
tumor-suppressor pathway during
lymphomagenesis, and alterations in
proteins that influence apoptosis can
change the frequency of ARF and/or
p53 inactivation (16–18). To assess
whether loss of Bcl-w affected the
frequency of ARF and/or p53 inactivation, we performed Western (Figure 3C and Supplemental Figure 4A)
and Southern (Supplemental Figure
4B) blot analyses of lymphomas from
mice of all 3 genotypes. As mutations in p53 typically result in protein
overexpression (16), we performed
sequencing of p53 on samples that
showed increased levels of p53 protein. We also sequenced p53 in lymphomas with increased ARF protein due to the negative feedback
regulation of ARF by p53. Only lymphomas with elevated p53 protein harbored mutations in the DNA-binding domain of p53, the
most frequently mutated region in p53 (19). Loss of Bcl-w resulted
in less frequent mutations of p53 (Table 1). p53 deletions are rare
in Eμ-MYC–Tg mice, and we detected no p53 deletions in any of
the lymphomas from mice of the 3 genotypes (Table 1 and Supplemental Figure 4B). We observed a decrease in the frequency of
jci.org   Volume 127   Number 2   February 2017
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Figure 5. BCL-W expression is regulated by MYC
through transcriptional upregulation of the miR-15
family. (A–C) A luciferase reporter containing the
3′-UTR of Bcl-w with a WT or mutated (Mut) miR-15
family binding site was transfected into p53–/– MEFs
expressing MYCER (A), MYCΔMBII-ER (B), or MYCV394D-ER (C). Luciferase activity was measured in
triplicate 48 hours after the addition of vehicle control (EtOH) or 4-OHT. A luciferase reporter containing
either the WT or mutated miR-15 family binding site
of the 3′-UTR of Bcl-2 served as a positive control for
A–C. A β-gal reporter was cotransfected for normalization purposes. (C and D) miR-15 family binding
sites in the 3′-UTR of Bcl-w and Bcl-2 were blocked
with site-specific small molecules (Target Protectors
[TP]) 24 hours prior to MYCV394D-ER activation.
Following the addition of 4-OHT, luciferase activity (C)
and protein levels (D) were assessed in the presence
or absence of the Bcl-w and Bcl-2 Target Protectors.
Data shown are representative of 2 to 4 independent
experiments. Error bars indicate the SD. *P = 0.0017
(A), by t test; *P < 0.0001 (B and C), by 1-way ANOVA.

Arf deletions in lymphomas that lacked Bcl-w (Table 1 and Supplemental Figure 4B). Together, these results suggest that, without
Bcl-w, the selective pressure to inactivate the ARF/p53 pathway
was reduced during lymphomagenesis.
MYC suppresses BCL-W expression. MYC activates apoptosis
by activating p53, but also by suppressing the expression of BCL-2
and/or BCL-XL independently of p53 (20–23). We investigated
whether BCL-W expression was regulated by MYC by expressing
MYCER in pre–B cells. Activation of MYCER with the addition of
4-OHT decreased BCL-W as well as BCL-2 and BCL-XL protein
levels (Figure 4A, left). Consistent with previous reports (20, 23),
protein levels of the antiapoptotic BCL-2 family member MCL-1
did not change following MYCER activation (Figure 4A, left). As
a separate, independent test of MYC regulation and to determine
whether MYC regulates BCL-W expression in vivo, we evaluated
spleens from precancerous Eμ-MYC mice and littermate-matched
non-Tg spleens. Eμ-MYC spleens had reduced BCL-W protein
levels as well as decreased BCL-2 and BCL-XL, but MCL-1 levels were unchanged compared with levels detected in the littermate-matched non-Tg spleens (Figure 4A, right). Evaluation of
Bcl-w mRNA by quantitative real-time PCR (qRT-PCR) showed
that, following MYCER activation in pre–B cells, Bcl-w mRNA levels decreased (Figure 4B, top panels). In addition, spleens from
precancerous Eμ-MYC mice had reduced levels of Bcl-w mRNA
compared with spleens from non-Tg littermates (Figure 4B, bottom panels). Taken together, MYC induces a decrease in BCL-W
mRNA and protein levels in B cells.
To determine whether the MYC-induced decrease in BCL-W
was cell-type specific, we also assessed WT MEFs expressing
MYCER. Analogous to the results we obtained in pre–B cells,
activation of MYCER in these nonhematopoietic cells decreased
BCL-W levels (Supplemental Figure 5). Likewise, BCL-2 and BCLXL levels were also reduced following MYCER activation (Sup640
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plemental Figure 5). Therefore, the MYC-induced decrease in
BCL-W also occurred in primary nonhematopoietic cells, indicating that this was a generalizable consequence of MYC activation.
Suppression of BCL-W expression is independent of MIZ-1 and
p53, but requires MYC transcriptional activity. To gain insight into
the mechanism by which MYC was modulating BCL-W expression, we performed a series of experiments using mutants of MYC.
MYC can suppress the expression of some genes by inhibiting the
transcriptional activator MIZ-1 (24). Using a mutant of MYCER
containing a point mutation interrupting the MYC:MIZ-1 interaction (MYCV394D-ER) (25), we determined that BCL-W protein
levels decreased in cells expressing MYCV394D-ER to an extent
similar to that seen in cells with WT MYCER following activation
with 4-OHT (Figure 4C). We also observed analogous reductions
of BCL-2 and BCL-XL, but not of MCL-1 (Figure 4C). To evaluate whether a transcriptionally competent MYC was required to
suppress BCL-W protein expression, we used a mutant of MYCER
lacking the MYC box II domain, which is crucial for MYC transcriptional activity (MYCΔMBII-ER) (24). Upon addition of 4-OHT, we
observed a decrease in BCL-W protein only in cells expressing
the WT MYCER, but not in cells expressing the transcriptionally
impaired MYCΔMBII-ER mutant (Figure 4D). The decrease in
BCL-W protein expression was reflected at the mRNA level, as a
reduction in Bcl-w mRNA only occurred in cells expressing WT
MYCER, but not the transcriptionally impaired MYCΔMBII-ER
(Figure 4E). These data demonstrate that MYC transcriptional
activity is required to downregulate BCL-W expression. Furthermore, the experiments using MYCER mutants were performed in
cells lacking p53 (Figure 4, C–E), indicating that the MYC-induced
decrease in BCL-W expression occurs independently of p53.
BCL-W expression is modulated by the MYC-regulated miR-15
family. Upon evaluation of publically available ENCODE MYC
ChIP-sequencing (ChIP-seq) data (26), MYC was not present at
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Figure 6. BCL-W expression is selected for in human BL. (A) qRT-PCR analysis (in triplicate) of samples from patients with BL (n = 15) compared with
normal lymphoid control tissue (n = 7). mRNA levels were normalized to β-actin and presented as 2–ΔΔCt. Bars represent the mean ± SEM. *P = 9.1 × 10–4,
by t test. (B) Microarray gene expression–profiling data for BCL-W and BCL-2 mRNA in BL (n = 57) compared with normal B cells (n = 49). Bars represent
the mean ± SEM. Each circle represents 1 sample, and the y axis represents normalized expression of BCL-W and BCL-2. *P = 1.8 × 10–8, by t test. The
data sets analyzed are listed in Supplemental Table 1. (C) Immunohistochemical analysis for BCL-W and BCL-2 protein was performed on samples from
patients with BL (n = 26). Box and whisker plots of pathologist scores and representative images of BCL-W and BCL-2 staining from the same tumor sample are shown. Original magnification, ×40; scale bars: 200 μm. *P < 0.0001, by t test. For the box and whisker plots, the box represents the 25th and 75th
percentiles, the line indicates the median, the circle indicates the mean, and the whiskers represent the maximum and minimum. (D) Protein expression
was assessed by Western blotting for the indicated proteins in BL and DLBCL cell lines. Controls included tissue from 2 human spleens and purified B
cells from human peripheral blood.

the Bcl-w promoter region in hematopoietic or nonhematopoietic
cell lines (Supplemental Figure 6). Therefore, we postulated that
MYC may be indirectly altering Bcl-w expression through miR. As
we (Supplemental Figure 7) and others (27–29) have shown, Bcl-w
mRNA is targeted and negatively regulated by the miR-15 family.
Recently, we reported that MYC transcriptionally upregulates this
miR family as a mechanism to downregulate Bcl-2 expression (22,
23). To test whether MYC activation leads to miR-15 family targeting of Bcl-w, we used a luciferase-based assay to detect direct binding of the miR-15 family to its predicted target site in the 3′-UTR
of Bcl-w following MYC-induced transcriptional upregulation.
Specifically, luciferase reporters harboring either a WT miR-15
family binding site of the Bcl-w 3′-UTR or a mutated version were
introduced into p53 –/– MEFs expressing the 4-OHT–inducible form
of MYCER. Upon activation of MYCER, we detected a decrease in
luciferase activity in cells containing the WT miR-15 family binding site, but not the mutated miR-15 family binding site (Figure
5A). As a positive control, we evaluated cells with WT or mutated
miR-15 family binding sites in the 3′-UTR of Bcl-2 and obtained
results analogous to those with the Bcl-w 3′-UTR (Figure 5A).
These results indicate that MYC induces the expression of miR15 family members, as we have recently reported (23), which then
directly bind and negatively regulate Bcl-w expression.
To further assess the mechanism by which MYC regulates the
miR-15 family to target Bcl-w, we used the transcriptionally incompetent form of MYC. p53-null MEFs expressing either the WT MYCER or the deletion mutant MYCΔMBII-ER were transfected with a

luciferase reporter containing the WT miR-15 family binding site
of either the Bcl-w 3′-UTR or, as a positive control, the Bcl-2 3′-UTR.
Following activation of WT MYCER, luciferase activity decreased
in cells containing the Bcl-w or Bcl-2 3′-UTR (Figure 5B). In contrast, after addition of 4-OHT to the MYCΔMBII-ER–expressing cells, we detected no change in luciferase activity for either
luciferase reporter (Figure 5B), indicating that a transcriptionally competent MYC is required for the miR-15 family–mediated
decrease in Bcl-w expression.
We further validated this MYC-regulated miR-mediated
mechanism by transfecting p53-null MEFs expressing the MYCER mutant unable to interact with MIZ-1 (MYCV394D-ER) with
modified RNA molecules (Target Protectors) designed to block
endogenous miR-15 family members from binding their target
site in the 3′-UTR of Bcl-w. In addition to the Target Protectors,
the MYCV394D-ER–expressing cells received luciferase reporters
containing the miR-15 family binding site for either the 3′-UTR of
Bcl-w or, as a control, Bcl-2. In the absence of any Target Protectors, MYCV394D-ER activation, which upregulates the miR-15
family (23), resulted in decreased luciferase activity in cells with
either the Bcl-w or Bcl-2 luciferase reporters (Figure 5C). However,
when the miR-15 family binding site of the Bcl-w or Bcl-2 3′-UTR
was blocked by their respective Target Protectors, luciferase activity remained unchanged (Figure 5C). As an additional control
to test the specificity of our system, cells containing the Bcl-w or
Bcl-2 3′-UTR luciferase reporters were transfected with the opposite Target Protector. Following MYCV394D-ER activation with
jci.org   Volume 127   Number 2   February 2017
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Table 2. Characteristics of BL and DLBCL patients for IHC
Characteristic
Patients
Median age, yr (range)
Sex, n (percentage)
Male
Female
NA
BCL-W, n (percentage)
0
1A
2A
3A
BCL-2, n (percentage)
0
1A
2A
3A

BL

DLBCL

n = 26
9 (3–20)

n = 57
64 (10–93)

17 (65.4%)
8 (30.8%)
1 (3.8%)

35 (61.4%)
19 (33.3%)
2 (3.5%)

3 (11.5%)
11 (42.3%)
7 (26.9%)
5 (19.2%)

7 (12.3%)
16 (28.1%)
18 (31.6%)
16 (28.1%)

22 (84.6%)
3 (11.5%)
1 (3.9%)
0 (0%)

15 (26.3%)
6 (10.5%)
14 (24.6%)
22 (38.6%)

Where duplicate or triplicate samples were available, scores were
averaged and rounded to the highest integer. NA, not available.

A

4-OHT, luciferase activity decreased to an extent that was similar
to that seen with no Target Protector present (Figure 5C). In addition, MYCV394D-ER activation decreased BCL-W and BCL-2 protein expression levels in the absence of any Target Protector (Figure 5D). However, BCL-W and BCL-2 levels remained unchanged
when their respective Target Protectors were present to block the
miR-15 family binding sites (Figure 5D). Together, these results
provide direct mechanistic data showing that MYC transcriptionally upregulates the miR-15 family members that then target and
decrease the expression of Bcl-w and that this occurs independently of both MIZ-1 and p53.
BCL-W is overexpressed in human BL. We recently reported
that the transformation status of the cell dictates whether MYC
functions as a transcriptional activator or repressor of the miR15 family (23). In normal, nontransformed cells, MYC transcriptionally upregulates the miR-15 family, which downregulates
Bcl-2 and, as we show here, Bcl-w expression, leading to increased
apoptosis. However, this apoptotic mechanism is inactivated in
cancer cells, as MYC is converted from a transcriptional activator
to a transcriptional repressor of the miR-15 family, which would
allow Bcl-2 and, presumably, Bcl-w levels to be increased in cancer
cells that overexpressed MYC (23).
We and others have reported that MYC-overexpressing murine
lymphoma cells have reduced expression of the miR-15 family due
to MYC-mediated repression (22, 23, 30). We evaluated miR-15a
expression in formalin-fixed, paraffin-embedded BL patient samples, which constitutively overexpress MYC due to a MYC translocation, a defining feature of this lymphoma (31). As expected,
miR-15a levels were significantly decreased in BL patient samples
compared with levels in normal controls (Supplemental Figure
8A), whereas levels of miR-17-5p, which is induced by MYC in cancer cells, were increased in the BL samples (Supplemental Figure
8B). Therefore, as in murine B cell lymphoma, miR-15a levels are
reduced in human B cell lymphoma.
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We next performed qRT-PCR to evaluate mRNA levels of
BCL-W and BCL-2 from RNA isolated from formalin-fixed, paraffin-embedded BL patient samples and normal lymph node
controls. Strikingly, BCL-W mRNA was overexpressed in the BL
patient samples compared with expression levels detected in the
normal tissue (Figure 6A and Supplemental Figure 9). Because
low or undetectable BCL-2 levels are typical in BL and considered
during diagnosis, BCL-2 levels were evaluated and showed no
overexpression compared with normal tissue (Figure 6A and Supplemental Figure 9). As a separate, independent analysis of BCL-W
mRNA expression in human BL, we evaluated publically available
microarray gene expression–profiling data (http://www.ncbi.nlm.
nih.gov/geo/). Consistent with our qRT-PCR data, BCL-W was
significantly overexpressed in BL samples compared with either a
mixed population of normal B cells or only normal germinal center
B cells (Figure 6B and Supplemental Figure 10). We also assessed
BCL-2 mRNA levels and determined that they were not elevated in
BL cells compared with levels in normal B cells (Figure 6B). These
data indicate that increased BCL-W mRNA expression is selected
for in human BL, whereas BCL-2 is not.
To determine whether the increase in BCL-W mRNA resulted in
increased BCL-W protein expression, we performed immunohistochemical analyses of samples from patients with BL. Blinded scoring by a hematopathologist revealed that expression of BCL-W protein was a very frequent event in BL. Specifically, 88.5% (23 of 26) of
the samples had positive staining (≥1 pathologist score) for BCL-W
(Figure 6C, Table 2, Supplemental Figure 11). Only 15.4% (4 of 26)
of the samples showed BCL-2 positivity, which was predominantly
low. Additionally, BCL-W protein was overexpressed in BL cell lines
compared with normal human splenic tissue and isolated B cells
(Figure 6D). Evaluation of BCL-W levels in B cell lymphomas from
Eμ-MYC–Tg mice showed a similarly high frequency of increased
BCL-W protein expression (Supplemental Figure 12). These results
indicate that, in addition to murine lymphoma, BCL-W may be a significant contributor to the pathogenesis of human BL.
Targeting BCL-W in MYC-driven BL induces apoptosis. Given that
BCL-W expression is highly selected for in BL, we tested whether
targeting BCL-W would affect BL cell survival. Because we have
established a link between Bcl-w and the miR-15 family, which is
repressed in BL, we hypothesized that increasing levels of the miR15 family in these lymphoma cells would decrease BCL-W expression, leading to apoptosis. To test this, we ectopically expressed the
miR-15a/16-1 cistron or empty vector as a control in 2 human BL
cell lines. In both BL cell lines, ectopic expression of miR-15a/16-1
decreased BCL-W protein expression (Supplemental Figure 13A).
Reduced levels of BCL-2 protein, which we previously reported occurred with ectopic expression of miR-15a/16-1 in murine
lymphoma cells (23), were also detected and served as a positive
control (Supplemental Figure 13A). The forced expression of miR15a/16-1 reduced cell growth, total cell numbers, and viability
(Supplemental Figure 13, B–D). Furthermore, ectopic miR-15a/16-1
expression induced apoptosis, as evidenced by the appearance of
cleaved caspase 3 (Supplemental Figure 13A). Therefore, increasing expression of the miR-15 family members that target and downregulate BCL-W and BCL-2 induces apoptosis of BL cells.
As an independent approach to specifically test the dependency of BL cells on BCL-W expression, we used a doxycycline-
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Figure 7. Targeting BCL-W induces apoptosis
in human BL. (A–D) The indicated human BL
cell lines were infected with a Dox-inducible
lentivirus encoding either a BCL-W shRNA
(shBW) or nontargeting (shNT) control shRNA.
Following the addition of Dox or DMSO vehicle
(Veh) control, Western blotting for cleaved
caspase 3 (A), MTS assays (B, in quadruplicate), and staining for subG1 DNA content (C,
in triplicate) and annexin V positivity (D, in
triplicate) were performed. (E and F) Daudi cells
were doubly infected with the Dox-inducible
lentivirus expressing either a BCL-W shRNA
(shBW) or nontargeting (shNT) control shRNA
and a retrovirus expressing BCL-W (+) or empty
vector control (–). Following the addition of Dox
(+) or DMSO vehicle control (–), Western blotting
for the indicated proteins (E) and MTS assays (F,
in quadruplicate) were performed. Data shown
are representative of 2 to 3 independent experiments. Error bars for B–D and F indicate the SD.
*P < 6.4 × 10–4 (B), *P < 0.025 (C), *P < 0.034 (D),
and *P < 0.0036 (F), by t test comparing shBW
and Dox with shBW and vehicle.

inducible (Dox-inducible) BCL-W shRNA in 3 human BL cell lines.
Following the addition of Dox to activate expression of the BCL-W
shRNA, BCL-W protein expression decreased (Figure 7A). This
resulted in reduced cell growth in all 3 BL cell lines (Figure 7B).
The reduction in cell growth was attributed to increased apoptosis, as indicated by the increased subG1 DNA content (Figure 7C),
annexin V positivity (Figure 7D), and caspase 3 cleavage (Figure
7A). To test whether the negative consequences of BCL-W shRNA
were specific and not due to off-target effects, BCL-W was ectopically expressed. BL cells with BCL-W shRNA and ectopic expres-

sion of BCL-W did not show a decrease in
growth or an increase in caspase 3 cleavage
after the addition of Dox, which was only
evident in BL cells expressing the BCL-W
shRNA alone following the addition of Dox
(Figure 7, E and F). These data indicate that
targeting BCL-W in BL, which selects for
increased BCL-W expression, may be an
effective therapeutic approach to treat BL.
As an additional test of the requirements of BCL-W for BL survival, we took
a pharmacological approach. The BH3
mimetic compounds ABT-737 and its analog ABT-263 directly activate apoptosis
by binding and inhibiting the antiapoptotic BCL-2 proteins BCL-2, BCL-XL, and
BCL-W (5). To evaluate the effect of ABT737 and ABT-263 on BL, we first determined the IC50 of each in 2 human BL cell
lines (Figure 8A). The IC50 for ABT-737 and
ABT-263 was 500 nM and 1 μM, respectively, for Daudi cells and 250 nM and 2.5
μM, respectively, for Ramos cells. To determine whether BCL-W expression alone
could protect the BL cells from ABT-737 and ABT-263, BCL-W was
ectopically expressed (Figure 8B and Supplemental Figure 14A)
and treated the BL cells with the IC50 of each. After 48 hours of
treatment with the BH3 mimetics, the growth of BL cells expressing the control vector was significantly diminished (Figure 8C and
Supplemental Figure 14B) as a result of increased apoptosis, as
indicated by the appearance of cleaved caspase 3 (Figure 8B and
Supplemental Figure 14A). However, cells overexpressing BCL-W
were not sensitive to ABT-737 or ABT-263, as growth of these cells
remained unaffected, and no caspase 3 cleavage was detected (Figjci.org   Volume 127   Number 2   February 2017
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Figure 8. Increased expression of BCL-W confers resistance to BL
cells to BH3 mimetics. (A) The IC50 of the BH3 mimetics ABT-737 and
ABT-263 for 2 human BL cell lines (Daudi and Ramos) was determined
using MTS assays (in quadruplicate, 48 h). (B–E) Daudi cells remained
uninfected (Un) or were retrovirally infected to express empty vector
(Vec), BCL-W (BW), or BCL-2 (B2). Following treatment with ABT-737
(+), ABT-263 (+), or DMSO vehicle control (–) at the determined IC50
(B–D) or the indicated concentrations (E) for 48 hours (B, C, and E) or
the indicated intervals (D), Western blotting for cleaved caspase 3 (B)
and MTS assays (C–E, in quadruplicate) were performed. Data shown
are representative of 2 independent experiments for both inhibitors.
For data in D and E, experiments with inhibitors were performed at the
same time but graphed separately, thus the DMSO control data are the
same. Error bars indicate the SD. *P < 6.67 × 10–6 ABT-737 and #P < 6.05
× 10–5 ABT-263 (ABT vs. DMSO) (C); *P < 2.69 × 10–4 ABT-737 and #P < 3.7
× 10–4 ABT-263 (vector with ABT vs. vector, BCL-W, or BCL-2 with DMSO)
(D); *P < 7.33 × 10–4 ABT-737 and #P < 0.011 ABT-263 (BCL-W or BCL-2
with ABT vs. BCL-W or BCL-2 with DMSO) (E), by t test.

ure 8, B and C and Supplemental Figure 14, A and B). Additionally,
4-day kinetics experiments also showed that BL cells with forced
overexpression of BCL-W were protected from the apoptosisinducing properties of the BH3 mimetics (Figure 8D and Supplemental Figure 14C). Finally, increasing concentrations of ABT-737
and ABT-263 were administered to BL cell lines to determine the
maximal dose at which the cells overexpressing BCL-W would no
longer be protected. BL cells with the vector control quickly succumbed to BH3 mimetic treatment, with all cells dying following
administration of 10 μM of either compound within 48 hours (Figure 8E and Supplemental Figure 14D). However, high concentrations (>50 μM) of either compound were necessary to kill the BL
cells overexpressing BCL-W (Figure 8E and Supplemental Figure
14D). Results similar to those with BCL-W overexpression were
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obtained by overexpressing BCL-2 for all experiments with the
BH3 mimetics (Figure 8 and Supplemental Figure 14). Collectively, these data show that BLs rely on BCL-W expression and
that increased BCL-W levels in BL cells confer resistance to the
BH3 mimetics ABT-737 and ABT-263.
BCL-W overexpression in diffuse large B cell lymphoma correlates with worse survival. Given our results with BL, we questioned whether BCL-W overexpression was specific to BL or
whether BCL-W may contribute to other human B cell lymphomas. We evaluated BCL-W protein levels in diffuse large
B cell lymphoma (DLBCL) cell lines, which often have dysregulated MYC activity. Increased BCL-W protein levels were
observed in the DLBCL cell lines compared with levels in the
normal controls (Figure 6D). Additionally, immunohistochemical analysis of DLBCL patient samples showed that BCL-W
protein was expressed in 87.7% (≥1 pathologist score) of the
patient samples (Figure 9A, Table 2, Supplemental Figure 15).
This frequency was consistent with the frequency (73.7%) we
observed for elevated BCL-2 levels in DLBCL (Supplemental
Figure 15), a known clinical feature of DLBCL (5). Additionally, while many DLBCL patient samples expressed both BCL-W
and BCL-2 protein, approximately a quarter of the samples
(26.3%) expressed only BCL-W protein and not BCL-2 protein
(Supplemental Figure 15B). Of these samples, the vast majority
(80%) had high (scoring a 2 or 3) BCL-W levels.
To determine whether the increase in BCL-W protein in DLBCL may be due to elevated mRNA levels, we performed qRT-PCR
on patient samples of DLBCL, with normal lymph nodes and
spleens serving as control lymphatic tissue. We determined that
BCL-W was significantly overexpressed in DLBCL compared
with levels detected in normal tissues (Figure 9B and Supplemental Figure 16). We obtained similar results for BCL-2 (Figure 9B
and Supplemental Figure 16), which served as a positive control.
Furthermore, we evaluated publically available microarray gene
expression–profiling data on DLBCL to determine whether our
mRNA results were reflected in larger patient populations (http://
www.ncbi.nlm.nih.gov/geo/). Both BCL-W and BCL-2 were significantly overexpressed in DLBCL compared with mixed populations of normal B cells or only germinal center B cells (Figure 9C
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Figure 9. Increased expression of BCL-W in DLBCL correlates with poor patient survival. (A) Immunohistochemical analysis for BCL-W and BCL-2 protein
was performed on samples from patients with DLBCL (n = 57). Box and whisker plots of pathologist scores and representative images of BCL-W and BCL-2
staining from the same 3 tumor samples. Original magnification, ×40; scale bars: 200 μm. For the box and whisker plots, the box represents the 25th
and 75th percentiles, the line indicates the median, the circle indicates the mean, and the whiskers represent the maximum and minimum. (B) qRT-PCR
analysis in triplicate of samples from patients with DLBCL (n = 26) compared with normal lymphoid control tissue (n = 10). mRNA levels were normalized
to β-actin and are presented as 2–ΔΔCt. Error bars represent the mean ± SEM. **P < 6.03 × 10–5 and *P = 0.014, by t test. (C) Microarray gene expression–
profiling data for BCL-W and BCL-2 mRNA in DLBCL (n = 319) compared with normal B cells (n = 49). Lines represent the mean ± SEM. Each circle represents
1 sample, and the y axis represents normalized expression of BCL-W and BCL-2. **P < 2.2 × 10–16 and *P = 9.96 × 10–5, by t test. The data sets analyzed
are listed in Supplemental Table 1. (D) Patient samples of DLBCL with low BCL-2 from the GSE31312 and GSE10846 data sets were each separated into 2
groups (BCL-W high and BCL-W low) on the basis of the median expression of BCL-W, and Kaplan-Meier analyses were performed. The P values in D were
determined by log-rank test.

and Supplemental Figure 17). Together, our data show that BCL-W
may also contribute to DLBCL.
Next, we questioned whether there was a correlation between
BCL-W and BCL-2 expression in DLBCL. Pearson’s correlations
were calculated for BCL-W and BCL-2 expression for 2 independent data sets. Independently, both data sets showed a negative
correlation between BCL-W and BCL-2 expression levels in DLBCL
patient samples (for GSE10846, R = –0.1687 and P = 2.9 × 10 –4; for
GSE31312, R = –0.0948 and P = 3.99 × 10–2). Given that BCL-W was
frequently overexpressed in DLBCL and survival rates of DLBCL
are not high, we questioned whether increased expression of
BCL-W correlated with DLBCL patient survival. To address this,
the same 2 DLBCL data sets were evaluated, as both contained

survival information. Because BCL-W expression was inversely
correlated with BCL-2 expression, we assessed the contribution
of increased BCL-W expression in samples with lower levels of
BCL-2. Specifically, patient samples were simultaneously stratified on the basis of the median expression of BCL-2 and BCL-W
into high or low expression groups for each gene. Then, using data
on those patients with low BCL-2 expression, Kaplan-Meier survival curves were plotted for the high and low BCL-W expression
groups. For both data sets, the patients with higher BCL-W levels
and low BCL-2 levels had significantly worse overall survival than
did those with lower levels of both BCL-W and BCL-2 (P = 0.0217
for GSE31312 and P = 0.0419 for GSE10846, log-rank tests, Figure 9D). Stratification of BCL-W expression for patients with high
jci.org   Volume 127   Number 2   February 2017
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Table 3. Analysis of overall survival in patients with DLBCL with low BCL-2 expression
Variables
GSE10846

GSE31312

Univariate
Age
Tumor stageA
BCL-W expression
Age
Tumor stageA
BCL-W expression

Multivariate

HR 95%

CI

P value

HR 95%

CI

P value

1.793
1.851
1.694
2.252
2.388
1.788

1.113–2.888
1.138–3.010
1.014–2.832
1.366–3.712
1.444–3.949
1.081–2.958

0.015
0.012
0.042
0.001
4.72 × 10–4
0.022

1.898
2.057
1.781
2.318
2.426
1.696

1.166–3.091
1.255–3.372
1.055–3.008
1.391–3.861
1.468–4.011
1.019–2.822

0.010
0.004
0.031
0.001
5.5 × 10–4
0.042

Early stages (I and II) versus late stages (III and IV). HR, hazard ratio.

A

BCL-2 expression levels did not show a statistically significant
difference in survival for those who overexpressed both. Next, we
performed univariate and multivariate Cox regression analyses on
both stratified data sets (with low BCL-2 expression), since additional prognostic variables (e.g., patient’s age and tumor stage)
were available. From the univariate analysis, we determined that
BCL-W expression, patient’s age, and tumor stage were significantly associated with overall survival (Table 3). Considering all
3 variables, multivariate Cox regression analysis indicated that
BCL-W expression independently correlated with overall survival
(Table 3). Together, these results indicate that BCL-W expression
is a predictive indicator and independent determinant of overall
survival in DLBCL patients with lower levels of BCL-2.

Discussion

Prior to the current study, BCL-W was not believed to be an
important contributor to hematopoietic cell survival. However,
this conclusion was never tested and was based solely on expression levels and on the observation that no overt hematopoietic cell
defects were detected in mice lacking Bcl-w (6–9). Here, our study
has revealed an unexpected and, in our view, significant function
for BCL-W in B cell survival and MYC-induced lymphomagenesis.
We also provide important mechanistic insight into the regulation
of BCL-W expression by MYC in both hematopoietic and nonhematopoietic cells. Most notably, our data provide striking evidence
of a survival role for BCL-W in both human BL and DLBCL that we
believe will have significant clinical implications.
Antiapoptotic BCL-2 family members inhibit death signals
elicited by a number of cellular stressors, including cytokine withdrawal and activation of MYC (2). Given the dogma regarding
BCL-W, we were initially surprised that in B cells, loss of Bcl-w
conferred sensitivity to IL-7 withdrawal and MYC activation.
Using multiple ex vivo and in vitro approaches, we demonstrated
that BCL-W significantly contributes to inhibiting MYC-induced
apoptosis in both hematopoietic and nonhematopoietic cells. Specifically, in the absence of BCL-W, primary pre–B cells and MEFs
were considerably more susceptible to MYC-induced apoptosis
than were cells that had WT BCL-W. Previously, it was reported
that B cells lacking other antiapoptotic BCL-2 family members
(BCL-2, BCL-XL, or MCL-1) were more sensitive to MYC-induced
apoptosis (32–34), whereas loss of proapoptotic BCL-2 family
members (BIM, BAX, PUMA, or NOXA) conferred resistance to
MYC-induced apoptosis (17, 18, 35, 36). The p53 pathway also
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mediates apoptosis due to MYC dysregulation (16, 37). There was
a decreased frequency of p53 pathway inactivation in the lymphomas that emerged in Eμ-MYC mice lacking Bcl-w, suggesting a
decreased selective pressure to inactivate the p53 pathway during
tumorigenesis. We previously reported that loss of the proapoptotic BCL-2 family member BAX altered the frequency of p53
inactivation in MYC-driven lymphomas (17). Together, our data
highlight a previously unknown function of BCL-W in apoptosis
triggered by deregulated MYC expression and suggest that BCL-W
may have cross-talk with the p53 pathway.
To our knowledge, no link has yet been established between
BCL-W expression and MYC activation. Here, we determined that
MYC regulates BCL-W expression and identified the underlying
mechanism through which this occurs. Specifically, we demonstrated that MYC suppressed the expression of BCL-W independently of its interaction with the transcriptional activator MIZ-1
and of p53, which has been reported to repress the expression
of the related family members Bcl-2 and Bcl-xl (38, 39). Furthermore, our data revealed that a transcriptionally competent
MYC was required for the reduction in BCL-W expression. However, there was no evidence of direct transcriptional activation
by MYC, suggesting that MYC was indirectly regulating the
expression of BCL-W. We (here) and others (27–29) have shown
that Bcl-w is a target of the miR-15 family, which is known to be
regulated by MYC (40). In addition, we recently demonstrated
that MYC downregulates the expression of BCL-2 and BCL-XL
by transcriptionally upregulating the levels of the miR-15 and
let-7 families, respectively (22, 23). Therefore, we hypothesized
that MYC was modulating the expression of BCL-W through the
miR-15 family. Using luciferase reporter assays and site-specific
small molecules designed to block the miR-15 family from binding the 3′-UTR of Bcl-w, we provided direct evidence that MYC,
through the miR-15 family, modulates BCL-W expression. These
data offer mechanistic evidence of a link between MYC, the miR15 family, and BCL-W and, we believe, significantly expand our
understanding of MYC-mediated apoptosis. Determining which
transcriptional targets of MYC are responsible for the biological
consequences of MYC dysregulation and how these are altered
during cellular transformation provides important insights into
lymphomagenesis. The data presented here, combined with previous findings (22, 23, 30, 40), indicate that MYC transcriptionally activates or represses miR to induce growth or apoptosis and
that this is altered in cancers.
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With our data showing that BCL-W is a critical mediator of
MYC-induced apoptosis, we hypothesized that loss of Bcl-w would
affect lymphomagenesis driven by dysregulated MYC. While
Bcl-w heterozygosity delayed MYC-induced lymphoma development, remarkably, Bcl-w –/– Eμ-MYC–Tg mice developed lymphoma with a substantially extended latency compared with that of
littermate-matched control Eμ-MYC mice. Specifically, Eμ-MYC
mice lacking both Bcl-w alleles had a mean lifespan that was more
than 3 times longer than that of their Bcl-w+/+ Eμ-MYC siblings.
By the time all of the Bcl-w+/+ Eμ-MYC mice had succumbed to
lymphoma, none of the Bcl-w –/– Eμ-MYC mice had developed
lymphoma. Reports of the effects of deleting other prosurvival
BCL-2 family members have shown differing results. For example, a Bcl-xl deficiency only slightly delayed Eμ-MYC lymphoma
development (33), whereas deletion of Bcl-2 did not significantly
alter lymphomagenesis (34). In contrast, loss of 1 allele of Mcl-1
profoundly delayed MYC-induced lymphoma development (41).
Therefore, although there are multiple antiapoptotic BCL-2 family members, they do not appear to equally contribute to MYCinduced B cell lymphomagenesis.
While lymphoma development was profoundly extended in
Bcl-w –/– Eμ-MYC mice, loss of Bcl-w did not impact the type of lymphoma that emerged. The lymphomas that arose, regardless of
genotype or time of tumor incidence, were characteristic Eμ-MYC
pre–B/B cell lymphomas. These observations suggested that the
B cell populations in which transformation occurs to generate
lymphomas in the Eμ-MYC mouse model (15) remained unaltered by loss of Bcl-w. Indeed, flow cytometric analysis revealed
that the B cell populations in the spleen and BM of precancerous
littermates were indistinguishable among the 3 genotypes. Previous reports using a transplant model with fetal liver–derived
stem cells from Eμ-MYC Bcl-2–/– (34) or Eμ-MYC Bcl-xl–/– (33) mice
documented reduced immature and mature or pro–B and pre–B
cells, respectively, which is consistent with the cell types in which
these proteins predominantly function (2). Despite having similar
biochemical functions, our data support the concept that specific antiapoptotic BCL-2 family members are more important than
other family members in different cell types or stages of differentiation (5). Knowing when and how individual prosurvival BCL-2
proteins are relied on during neoplastic transformation may provide additional strategies for treating MYC-driven lymphoma.
MYC is overexpressed and/or dysregulated in the majority of
human cancers (3); therefore, we believe that our results demonstrating an essential role for BCL-W in MYC-induced lymphomagenesis have significant implications for cancer biology and
therapy. Importantly, we exposed a previously unknown connection between BCL-W and the MYC-driven human BL, a lymphoma for which no other antiapoptotic BCL-2 family member has
been linked. Using a combination of approaches, we showed that
increased BCL-W expression is highly selected for in BL. Specifically, 88.5% of the patient samples expressed BCL-W protein,
whereas only 15.4% expressed BCL-2. These data were supported
by analyses of BCL-W and BCL-2 mRNA from BL patient samples,
which showed that elevated levels of BCL-W mRNA were preferentially selected for, but BCL-2 was not. Furthermore, we demonstrate that knocking down BCL-W expression in human BL cell
lines resulted in apoptosis, highlighting the importance of main-

taining BCL-W levels in BL for continued cell survival. Additionally, elevated levels of BCL-W alone conferred resistance to BL cell
lines to the apoptotic effects of the BH3 mimetic compounds ABT737 and ABT-263, which target 3 antiapoptotic BCL-2 family members. Previously, it was reported that BCL-2 expression correlated
with sensitivity to ABT-263 in a panel of human non-Hodgkin lymphoma cell lines (42) and sensitivity to ABT-737 in human chronic
lymphocytic leukemia (43, 44), small-cell lung cancer cell lines
(45), and Eμ-MYC lymphomas (46, 47). In addition, increased
levels of other antiapoptotic family members, such as MCL-1
and BCL-XL, have also been shown to confer resistance to ABT737 (42). Therefore, our data indicate that expression of BCL-W
will likely need to be considered and monitored when using BH3
mimetics for the treatment of lymphomas. Moreover, our data
suggest that BCL-W may be useful in the diagnosis of BL and aid
in the development of targeted therapies for this malignancy.
We also investigated BCL-W in DLBCL with respect to BCL-2, a
known contributor to DLBCL that, when overexpressed, correlates
with reduced patient survival (5, 48). We determined that many
samples from DLBCL patients expressed both BCL-W and BCL-2
protein, but approximately a quarter of the samples only expressed
BCL-W protein, and of these, the vast majority had high BCL-W
levels. Furthermore, gene expression profiling of large DLBCL data
sets also showed an increase in BCL-W mRNA in DLBCL compared
with normal B cells. We also determined that there was a negative
correlation between BCL-W and BCL-2 levels in DLBCL, indicating
that there may be a significant subset of DLBCL cells that preferentially selects for the overexpression of BCL-W rather than BCL-2.
Importantly, those patients whose lymphoma did preferentially
select for BCL-W overexpression while BCL-2 levels remained low
had markedly worse survival rates, and in this context, the level of
BCL-W was also an independent determinant of overall survival
in patients with DLBCL. Of note, there was no additive negative
affect on patient survival when both BCL-2 and BCL-W were overexpressed, suggesting that lymphoma cell survival is not further
enhanced once a certain expression level of antiapoptotic BCL-2
family members is reached. In support of this concept, it has been
hypothesized that a mechanism of resistance to the BH-3 mimetics involves the upregulation of other antiapoptotic BCL-2 family
members that are not inhibited by the compounds (5). Therefore,
our data show that BCL-W expression is an important contributor
to and predictive indicator of DLBCL. Thus, BCL-W may serve as
a novel biomarker for BL and more aggressive DLBCL. Collectively, our data indicate that BCL-W is an understudied contributor to
lymphomas that could be added to the limited list of current predictive biomarkers to improve prognostication and the development of more effective individualized treatment strategies.

Methods

Mice. C57Bl/6 Eμ-MYC-Tg mice (4) were mated with C57Bl/6 Bcl-w+/–
mice (9) provided by Rosalind Segal (Harvard Medical School, Harvard University, Boston, Massachusetts, USA), and their offspring
were intercrossed to obtain littermate-matched Bcl-w+/+, Bcl-w+/–,
and Bcl-w –/– Eμ-MYC–Tg mice of both sexes. Only Eμ-MYC–Tg–positive males were mated to pass on the Tg. For survival studies, mice
were sacrificed at humane endpoints, and tumors and tissues were
harvested and analyzed.
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Lymphoma phenotype and B cell development analysis. Splenocytes and BM from littermates (prior to lymphoma development for
Eμ-MYC–Tg mice) or lymphoma cells were analyzed by flow cytometry following incubation with fluorochrome-linked antibodies as previously reported (49, 50).
Patient samples and tissue acquisition. Normal human B cells were
purified from leukoreduction filters obtained from the Red Cross
using the IMag Human B Lymphocyte Enrichment Set (BD Biosciences). Deidentified fresh spleens were obtained from the Cooperative Human Tissue Network at Vanderbilt University Medical Center
(VUMC) (Nashville, Tennessee, USA). For immunohistochemical
analysis of DLBCL, formalin-fixed, paraffin-embedded (FFPE) tissues were selected from archival pathology materials on the basis of
a documented large B cell diagnosis. Two separate tissue microarrays
(TMAs) were constructed using 2-mm diameter cores from 35 separate specimens represented in duplicate and 20 separate specimens
represented in triplicate, respectively. In addition, 10 samples with
high-grade morphologic features were examined as individual slides.
Fifty-seven DLBCL samples were considered evaluable and included
in the analyses. For qRT-PCR analysis of DLBCL, TissueScan cDNA
arrays containing 26 samples from patients with DLBCL and 10 normal lymphoid tissue controls were obtained from OriGene. For immunohistochemical analysis of BL, slides from 28 deidentified patients
diagnosed with BL were obtained from St. Jude Children’s Research
Hospital (Memphis, Tennessee, USA). Twenty-six BL samples were
considered evaluable and included in the analyses. Patient characteristics are listed in Table 2, and details on how the pathologist scored
IHC are provided in Supplemental Figures 11 and 15. For qRT-PCR
analysis of BL samples, 15 FFPE BL samples and 7 FFPE normal lymphoid control tissues were obtained from Thomas Jefferson University
(Philadelphia, Pennsylvania, USA).
IHC. Immunohistochemical analysis was performed on 4-μm
sections from BM preparations with anti–BCL-W (sc-6172; Santa Cruz
Biotechnology Inc.) and anti–BCL-2 (PA0117; Leica Biosystems). A
Leica BOND-MAX stainer was used with the Bond Polymer Refine
detection system for visualization (Leica Biosystems). Expression
levels were scored by a practicing board-certified hematopathologist
(ASK) on a 0–3 point scale in a blinded fashion and scoring only the
neoplastic cells. After unblinding, scores for the replicate samples on
the TMAs were averaged and a final score obtained.
Vectors. MSCV-MYCER-IRES-GFP, MSCV-MYCΔMBIIER-IRESGFP (MYC box II deletion mutant), and MSCV-MYCV394D-ER-IRESGFP (MYC:MIZ-1 interaction mutant) bicistronic retroviral vectors have
been previously described (23, 37). Luciferase reporter plasmids were
constructed by cloning a 60-mer of the 3′-UTR of Bcl-w containing the
predicted miR-15 family target sequence into pMIR-REPORT (Invitrogen, Thermo Fisher Scientific). Luciferase reporters containing mutated miR binding sites were similarly generated by cloning a 60-mer with
a mutated (base substitutions) target sequence to prevent the miR-15
family from binding the 3′-UTR of Bcl-w into pMIR-REPORT. Both
luciferase plasmids for the Bcl-2 3′-UTR have previously been reported (23). For luciferase assays, a reporter plasmid encoding β-gal was
used for transfection normalization (Invitrogen, Thermo Fisher Scientific). For knockdown experiments, nontargeting and BCL-W shRNA
sequences were cloned into the pInducer Dox-inducible shRNA system
(51). To induce shRNA expression, cells were treated with 1 μg/ml Dox
(Sigma-Aldrich) or vehicle control (DMSO). For overexpression and res648
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cue experiments, retroviral vectors were generated to express BCL-W
(MSCV-BCLW-IRES-RFP) or BCL-2 (MSCV-BCL2-IRES-RFP).
Cells, infection, and transfection. Daudi, Ramos, Raji, Su-DHL-6, and
NIH3T3 cells were cultured as described by the American Type Culture
Collection (ATCC). OCI-Ly-19 and OCI-Ly-3 cells were cultured in
RPMI-1640 containing 10% FBS. All cell lines were negative for MYCoplasma. MEFs were generated and cultured as previously described
(37). Primary murine pre–B cell cultures were generated as previously described (16). Briefly, BM was harvested from 8- to 10-week-old
Bcl-w+/+, Bcl-w+/–, and Bcl-w –/– littermate-matched mice or 4- to 6-weekold littermate-matched Eμ-MYC–Tg mice (prior to lymphoma development) with 1, 2, or no Bcl-w alleles. After red blood cell lysis, BM cells
were cultured in RMPI supplemented with 10 ng/ml IL-7, 20% FBS, 55
μM β-mercaptoethanol, 2 mM glutamine, and penicillin-streptoMYCin.
Primary pre–B cells and MEFs were infected with bicistronic retroviral
vectors (described above) in the presence of 8 μg/ml polybrene as previously described (37). GFP-positive pre–B cells were isolated by fluorescence-activated cell sorting. Human BL cell lines were infected with
Dox-inducible lentiviral vectors (see above) expressing either a nontargeting shRNA or BCL-W–targeting shRNA and/or retroviral vectors
expressing either BCL-W or BCL-2 cDNA or empty vector control. p53–/–
MEFs were transfected using Lipofectamine 2000 (Invitrogen, Thermo
Fisher Scientific) with 200 nM miScript Target Protector for Bcl-w or
Bcl-2 (QIAGEN) according to the manufacturers’ protocols.
Western blotting. Whole-cell protein lysates were generated, and
equal amounts of protein per lane were Western blotted as previously described (16). The following antibodies were used: p19ARF
(GTX200780; GeneTex); p53 (Ab-7; Calbiochem); BCL-W (31H4,
product no. 2724) and cleaved caspase 3 (Asp175, product no. 9661)
(both from Cell Signaling Technology); BCL-2 (3F11) and BCL-XL
(44/BCL-X) (both from BD Bioscience); MCL-1 (200-401-CR9;
Rockland); MYC (9E10; EMD Millipore); and β-actin (AC-15; SigmaAldrich). p53 cDNA was sequenced as previously described (16).
Growth and apoptosis analyses. For IL-7 deprivation experiments,
BM-derived primary pre–B cells were washed twice with PBS and
resuspended in complete media (described above) without IL-7. To
activate MYCER, 1 μM 4-hydroxytamoxifen (4-OHT; Sigma-Aldrich)
or vehicle control (EtOH) was added to culture media. Population doublings, cell numbers, and/or viability were determined by trypan blue
dye exclusion (in triplicate) and proliferation by MTT (Sigma-Aldrich;
560 nm) or MTS (Promega; 490 nm) assays (in quadruplicate). Apoptosis was evaluated by Western blotting for cleaved caspase 3 (described
above) and flow cytometry following propidium iodide (sub-G1/apoptotic DNA content) or annexin V/7-AAD staining (both in triplicate) as
previously reported (52). The ABT-737 and ABT-263 compounds were
obtained from Selleckchem and reconstituted with DMSO.
qRT-PCR. Total RNA was isolated from cell lines using TRIzol
(Invitrogen, Thermo Fisher Scientific) or the RecoverAll Total Nucleic
Acid Isolation Kit for FFPE tissue (Thermo Fisher Scientific) according to the manufacturer’s protocols. cDNA was generated and SYBR
Green (SABiosciences, QIAGEN) and TaqMan MicroRNA (Applied
Biosystems) assays were performed in triplicate to measure mRNA
and miR, respectively, as previously described (53, 54). qPCR of lymphoma TissueScan cDNA arrays (OriGene) was completed according
to the manufacturer’s protocol. mRNA and miR expression was normalized to β-actin and RNU6b, respectively, and presented as 2–ΔΔCt.
Primer sequences for mouse and human BCL-W, BCL-2, BCL-XL,
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MCL-1, and β-actin mRNA expression were obtained from the Harvard
Medical School Primer Bank (55).
Luciferase assays. p53–/– MEFs expressing the 4-OHT–inducible
WT MYCER, MYCΔMBII-ER, or MYCV394D-ER were transfected
in triplicate with luciferase reporters (described above), β-gal control plasmid, and/or 200 nM miScript Target Protectors (QIAGEN)
designed to block miR-15 family binding sites in the 3′-UTR of Bcl-w
and Bcl-2. Luciferase and β-gal activity was measured 24 hours after
MYCER activation as previously described (23).
Microarray gene expression analysis. Microarray gene expression
profiling data for BL, DLBCL, and normal human B cells (germinal
center centroblasts and centrocytes, naive B cells, and memory B
cells) were generated on the Affymetrix Human Genome U133 Plus
2.0 platform following the standard Affymetrix protocol. Data sets
(summarized in Supplemental Table 1) were downloaded from the
NCBI’s Gene Expression Omnibus (GEO) database (56) or from the
authors’ website. BL, DLBCL, and normal B cell CEL files were normalized using a robust multiarray average algorithm (57). Batch effects
were adjusted using ComBat (58). Probe sets were averaged to obtain
a single-expression intensity measure per gene per array. Differential
expression was measured by an unpaired, 1-tailed t test. All analyses
were carried out in R, version 3.2.3.
Patient survival and correlation analyses. Two microarray gene
expression–profiling data sets for DLBCLs (59, 60) were generated
on the Affymetrix Human Genome U133 Plus 2.0 platform following
the standard Affymetrix protocol. These data sets and clinicopathological information were downloaded from the NCBI’s GEO database (GSE10846 and GSE31312). For each data set, raw expressionprofiling data (CEL files) were normalized using a robust multiarray
average algorithm (57). Probe sets were averaged to obtain a singleexpression intensity measure per gene per array. For survival analyses, patient samples were simultaneously stratified on the basis of the
median expression of BCL-2 and BCL-W into high or low expression
groups for each gene. Then, using data on those patients with low
BCL-2 expression, Kaplan-Meier survival curves were plotted for the
high and low BCL-W expression groups and compared using log-rank
tests. Univariate and multivariate Cox proportional hazards regression analyses for overall DLBCL survival outcomes based on BCL-W
expression when BCL-2 expression was low were also performed.
Tumor stages were stratified into lower (I and II) and higher (III and
IV) stages. Patients were divided into lower and higher age groups on
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the basis of the median age. Survival analyses were carried out using
the R survival package, version 3.2.3.
Statistics. A 1-tailed Student’s t test was used when comparing 2
groups. One-way ANOVA was performed with Bonferroni’s correction
when comparing multiple groups. Survival curves were compared by
log-rank tests. The figure legends indicate the statistical tests used,
which groups were compared, and when values represent the mean ±
SD or the mean ± SEM. Univariate and multivariate survival analyses
were analyzed by Cox proportional hazards regression models. The
Pearson’s correlation coefficient was used to determine the association between BCL-W and BCL-2 expression. A P value of less than 0.05
was considered statistically significant.
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by the IACUCs and/or IRBs of VUMC and Thomas Jefferson University. All deidentified human tissues were obtained from the Cooperative
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